Retatrutide vs Semaglutide: Triple Agonist vs the GLP-1 Reference
Semaglutide is the most-cited GLP-1 mono-agonist in modern metabolic research — the compound that established the modern weight-loss evidence base with the STEP program and cardiovascular evidence with SELECT. Retatrutide sits four receptor-architecture steps up the ladder: it activates GLP-1, GIP, and glucagon receptors simultaneously, producing the largest weight-loss effect sizes seen in obesity trials to date.
For a research team choosing between them, the question is whether the protocol calls for the canonical mono-pathway reference compound (Semaglutide) or the frontier multi-pathway tool (Retatrutide). Both ship as lyophilized powder at ≥99% HPLC purity, but their pharmacology, dosing schedules, and research use cases are markedly different.
Retatrutide
Full entry →- Class
- GLP-1 / GIP / glucagon triple agonist
- Half-life
- ~6 days
- Dose
- 1 → 12 mg/week titrated
- Route
- subq
Semaglutide
Full entry →- Class
- GLP-1 receptor agonist
- Half-life
- ~7 days
- Dose
- 0.25 → 2.4 mg/week (titrated over 16+ weeks)
- Route
- subq
Key differences at a glance
| Property | Retatrutide | Semaglutide |
|---|---|---|
| Receptor target | GLP-1 + GIP + Glucagon (triple) | GLP-1 only (mono) |
| Class | Tri-incretin agonist | GLP-1 agonist |
| Half-life | ~6 days | ~7 days |
| Administration | Subcutaneous, once weekly | Subcutaneous, once weekly |
| Typical research dose | 2 → 12 mg/week (titrated) | 0.25 → 2.4 mg/week (titrated) |
| Weight-loss magnitude (Phase 2 / STEP) | ~24% body weight at 48 weeks (12 mg) | ~15% body weight at 68 weeks (2.4 mg) |
| Published trial breadth | Phase 2 published; Phase 3 ongoing | STEP 1–8, SUSTAIN, SELECT — fully mature |
| Cardiovascular evidence | In progress | SELECT trial showed MACE reduction (2023) |
Architectural gap: mono vs triple
Semaglutide activates a single receptor — GLP-1. The downstream cascade (insulin secretion, glucagon suppression, gastric emptying delay, hypothalamic appetite signaling) is well-characterized across nearly two decades of literature. The mono-pathway makes Semaglutide the cleanest research tool for questions isolating GLP-1 mechanism — confounders from other incretin pathways are absent.
Retatrutide activates three receptors simultaneously: GLP-1 (the canonical incretin pathway), GIP (adipocyte and lipid-handling effects), and glucagon (energy expenditure). The combination produces effect sizes that exceed any mono-agonist by a wide margin, but the multi-pathway architecture means researchers cannot use Retatrutide to isolate any single mechanism. The two compounds answer different research questions.
Trial data and dose-magnitude comparison
The STEP 1 trial (Wilding et al., 2021, NEJM) established Semaglutide's ~15% body-weight reduction at 68 weeks for the 2.4 mg/week dose in non-diabetic overweight/obese adults. SELECT (Lincoff et al., 2023, NEJM) added the cardiovascular endpoint — significant MACE reduction independent of weight loss — that reframed GLP-1 as cardio-protective.
Retatrutide's Phase 2 trial (Jastreboff et al., 2023, NEJM) at 12 mg/week produced ~24% body-weight reduction at 48 weeks. Direct head-to-head data is not yet published, but the Phase 2 numbers strongly suggest a larger effect size than Semaglutide at matched protocol timepoints. Phase 3 trials currently underway will produce the definitive comparison.
When to pick each
Pick Retatrutide when
- Magnitude of effect is the primary endpoint — Retatrutide Phase 2 shows the largest weight-loss numbers in the class.
- Research question touches glucagon-receptor energy expenditure or multi-receptor signaling.
- You want frontier triple-agonist data alongside or against established dual / mono baselines.
Pick Semaglutide when
- You need the longest and most-replicated trial record (STEP 1–8, SUSTAIN, SELECT).
- Research question requires mono-GLP-1 mechanism isolation without GIP / glucagon confounders.
- Cardiovascular-outcome research where SELECT trial evidence is the canonical reference.
Frequently asked
Why is Retatrutide so much more potent on weight loss?
Two compounding reasons: (1) it activates three receptors instead of one, producing additive metabolic effects; (2) the glucagon component adds direct energy-expenditure stimulation that Semaglutide does not provide. The Phase 2 effect-size is roughly 1.5–2x Semaglutide at matched timepoints, though direct head-to-head trials are still in progress.
Is Retatrutide FDA-approved?
No — Retatrutide is in Phase 3 trials. Semaglutide (as Ozempic / Wegovy) is FDA-approved for diabetes and weight management. LifeSpanSupply stocks Retatrutide strictly as a research reagent for laboratory use, not for human administration outside a research setting.
Can I substitute one for the other?
In research contexts, no. The compounds answer different questions: Semaglutide for mono-GLP-1 mechanism work and the canonical reference base; Retatrutide for frontier multi-incretin work and magnitude-maximizing protocols. The dosing schedules are also very different — Semaglutide titrates to 2.4 mg/week, Retatrutide titrates to 12 mg/week — not interchangeable.
Which one has more side effects?
Both share the GLP-1-class GI side-effect profile (nausea, constipation, GERD), particularly during dose escalation. Phase 2 Retatrutide showed comparable GI-event rates to historical GLP-1 trials at matched protocol stages. Both benefit from slow titration. The glucagon-receptor pathway in Retatrutide adds a small hepatic-glucose signal that researchers monitor in trial protocols.
Shop Retatrutide
All products →Comparison guides summarize research-context differences. All compounds are chemical reagents for laboratory analysis. See our Terms & Conditions.
